These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 21138791)
1. Molecular modeling based approach, synthesis and in vitro assay to new indole inhibitors of hepatitis C NS3/4A serine protease. Ismail NS; Hattori M Bioorg Med Chem; 2011 Jan; 19(1):374-83. PubMed ID: 21138791 [TBL] [Abstract][Full Text] [Related]
2. Computer based design, synthesis and biological evaluation of novel indole derivatives as HCV NS3-4A serine protease inhibitors. Ismail NS; El Dine RS; Hattori M; Takahashi K; Ihara M Bioorg Med Chem; 2008 Sep; 16(17):7877-87. PubMed ID: 18752958 [TBL] [Abstract][Full Text] [Related]
3. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894 [TBL] [Abstract][Full Text] [Related]
4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. Tsantrizos YS Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268 [TBL] [Abstract][Full Text] [Related]
5. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors. Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802 [TBL] [Abstract][Full Text] [Related]
6. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template. Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222 [TBL] [Abstract][Full Text] [Related]
7. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065 [TBL] [Abstract][Full Text] [Related]
8. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques. Wei HY; Lu CS; Lin TH J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210 [TBL] [Abstract][Full Text] [Related]
9. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells. Hamill P; Jean F Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392 [TBL] [Abstract][Full Text] [Related]
10. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116 [TBL] [Abstract][Full Text] [Related]
11. Novel azapeptide inhibitors of hepatitis C virus serine protease. Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors. Sheng XC; Pyun HJ; Chaudhary K; Wang J; Doerffler E; Fleury M; McMurtrie D; Chen X; Delaney WE; Kim CU Bioorg Med Chem Lett; 2009 Jul; 19(13):3453-7. PubMed ID: 19477126 [TBL] [Abstract][Full Text] [Related]
13. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening. Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413 [TBL] [Abstract][Full Text] [Related]
14. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease. Arasappan A; Njoroge FG; Chen KX; Venkatraman S; Parekh TN; Gu H; Pichardo J; Butkiewicz N; Prongay A; Madison V; Girijavallabhan V Bioorg Med Chem Lett; 2006 Aug; 16(15):3960-5. PubMed ID: 16730985 [TBL] [Abstract][Full Text] [Related]
16. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease. Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161 [TBL] [Abstract][Full Text] [Related]
18. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex. Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035 [TBL] [Abstract][Full Text] [Related]